INIS
patients
100%
risks
69%
reviews
55%
genetics
47%
symptoms
45%
psychoses
42%
brain
37%
data
37%
levels
30%
interventions
29%
control
28%
adults
27%
populations
24%
comparative evaluations
24%
interactions
22%
genes
21%
people
19%
guidelines
19%
assessments
18%
drugs
16%
children
15%
spectra
14%
sampling
14%
netherlands
13%
therapy
12%
sex
12%
performance
11%
nervous system diseases
10%
recommendations
10%
psychological behavior
10%
adolescents
9%
pain
9%
trauma
9%
testing
9%
females
8%
humans
8%
quality of life
8%
diseases
8%
doses
8%
design
8%
surveys
8%
management
8%
prediction
8%
women
7%
phenotype
7%
males
7%
information
7%
mental disorders
7%
covid-19
7%
variations
7%
implementation
7%
nmr imaging
6%
evaluation
6%
volume
6%
education
6%
clinical trials
6%
sleep
6%
values
6%
screening
6%
datasets
6%
size
6%
dopamine
6%
range
6%
blood
5%
eyes
5%
antidepressants
5%
cost
5%
side effects
5%
receptors
5%
applications
5%
safety
5%
communities
5%
carriers
5%
weight
5%
stimulation
5%
dynamics
5%
Keyphrases
Schizophrenia
28%
Meta-analysis
19%
Psychosis
18%
22q11.2 Deletion Syndrome
17%
Antipsychotics
16%
Psychotic Experiences
13%
Systematic Meta-analysis
13%
Netherlands
13%
Mental Health
12%
Experience Sampling
12%
First-episode Psychosis
12%
Healthy Controls
12%
Exposome
12%
Psychiatric Disorders
12%
Obsessive-compulsive Disorder
11%
Patients with Schizophrenia
10%
Psychiatry
10%
Severe Mental Illness
10%
Randomized Controlled Trial
10%
Polygenic Risk Score
10%
Dutch Pharmacogenetics Working Group
10%
Clozapine
10%
Copy number Variation
10%
Dutch
9%
Physical Activity
9%
Schizophrenia Spectrum Disorders
8%
Social Functioning
8%
Drug-gene Interaction
8%
Neurodevelopmental Disorders
8%
Psychotic Disorders
8%
Clinical High Risk for Psychosis (CHR-P)
7%
Posttraumatic Stress Disorder
7%
People with Severe Mental Illness
7%
Quality of Life
7%
Genetic Risk
7%
Lifestyle Intervention
7%
Mental Health Care
7%
Scoping Review
6%
Depressive Symptoms
6%
Psychopathology
6%
Systematic Literature Review
6%
Physical Activity Intervention
5%
Physical Health
5%
Pharmacogenetics
5%
Sibling Controls
5%
Psychiatric Conditions
5%
Environmental Factors
5%
Antidepressants
5%
Cytochrome P450 2D6 (CYP2D6)
5%
Clinical Outcomes
5%
Risk Factors
5%
Dementia
5%
Major Depressive Disorder
5%